FDA Approves Celltrion’s Avtozma for Pediatric COVID-19 in High-Risk Patients
Celltrion announced on October 7 that the U.S. Food and Drug Administration has approved an expanded pediatric indication for the intravenous...
Search results for "autoimmune disease"
Celltrion Files Phase 4 IND with FDA to Support 240 mg High-Dose Zymfentra Regimen in US
Celltrion has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for a Phase 4 clinical trial of Zymfentra...
Hanmi Completes Key Phase 2 Dosing for Once-Weekly Rare Disease Drug Efpeglucagon
During normal digestion, dietary carbohydrates convert into glucose that circulates in the blood.
Beyond ‘Getting Older’: 3 Major Joint Diseases That Strike in Middle Age
You wake up with stiff, unyielding fingers. Climbing a few flights of stairs leaves your knees throbbing.
BTS Member V Reveals 70% Hearing Loss in Right Ear: What Could Be Behind It?
BTS member V disclosed during a recent livestream that he has been receiving medical treatment for significant hearing...
Blurry Vision and Sudden Limb Weakness Could Signal Multiple Sclerosis, Not Just Stroke
When vision suddenly turns cloudy in one eye and an arm or leg feels unexpectedly weak, many patients immediately fear...
Celltrion Secures Dominant Market Share in Asia Led by Autoimmune and Oncology Biosimilars
Celltrion is consolidating its leading market position across major Asian countries with its key autoimmune and...
VOYXACT Preserves Kidney Function for Two Years in Phase 3 IgA Nephropathy Trial
Otsuka Pharmaceutical’s VOYXACT (active ingredient: sibeprenlimab) demonstrated long-term kidney protection by...
Losing Weight Despite a Big Appetite? Blame Your Thyroid, Not the Summer Heat
On scorching summer days, it is easy to blame the weather when you sweat excessively, feel drained, or lie awake at...
CAR-T Without Extracting Patient Cells? J&J Makes $785 Million Bet on In Vivo Therapy
Johnson & Johnson (J&J) is investing more than $785 million (approximately 1.11 trillion won) in next-generation "in...